Eyepoint Pharmaceuticals’ (EYPT) Buy Rating Reiterated at Guggenheim

Posted by Brian Himes on Jun 24th, 2026

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report)‘s stock had its “buy” rating reissued by Guggenheim in a report issued on Wednesday,Benzinga reports. They presently have a $68.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 365.56% from the company’s current price.

Several other research firms have also commented on EYPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright boosted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Royal Bank Of Canada cut their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Citigroup lifted their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Finally, Chardan Capital boosted their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $37.83.

View Our Latest Analysis on EYPT

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $14.61 on Wednesday. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.14 and a beta of 1.72. The business has a 50 day moving average of $13.26 and a 200 day moving average of $14.64. Eyepoint Pharmaceuticals has a 1-year low of $8.88 and a 1-year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. As a group, sell-side analysts anticipate that Eyepoint Pharmaceuticals will post -3.09 EPS for the current year.

Insider Activity

In related news, insider Ramiro Ribeiro sold 2,437 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.13% of the company’s stock.

Institutional Trading of Eyepoint Pharmaceuticals

Several large investors have recently added to or reduced their stakes in EYPT. Suvretta Capital Management LLC raised its holdings in Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock worth $143,012,000 after purchasing an additional 1,634,970 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Eyepoint Pharmaceuticals by 9.7% during the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after buying an additional 600,000 shares during the period. Federated Hermes Inc. increased its position in shares of Eyepoint Pharmaceuticals by 36.3% during the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock valued at $109,938,000 after buying an additional 1,601,101 shares during the period. Franklin Resources Inc. raised its stake in Eyepoint Pharmaceuticals by 19.3% in the fourth quarter. Franklin Resources Inc. now owns 4,976,915 shares of the company’s stock worth $90,928,000 after buying an additional 805,031 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Eyepoint Pharmaceuticals by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock worth $88,100,000 after buying an additional 1,027,623 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

(Get Free Report)

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.